Sildena®l citrate has been shown to be effective in a wide range of patients with erectile dysfunction and has been approved in the United States for this indication. The overall clinical safety of oral sildena®l, a potent inhibitor of phosphodiesterase type 5, in the treatment of erectile dysfunction was evaluated in more than 3700 patients (with a total of 1631 years of exposure worldwide). Safety and tolerability data were analysed from a series of double-blind, placebocontrolled studies and from 10 open-label extension studies of sildena®l in the treatment of erectile dysfunction. A total of 4274 patients (2722 sildena®l, 1552 placebo; age range 19±87 y) received double-blind treatment over a period of up to six months' duration, and 2199 received long-term, open-label sildena®l for up to 1 y. The most commonly reported adverse events (all causes) were headache (16% sildena®l, 4% placebo),¯ushing (10% sildena®l, 1% placebo), and dyspepsia (7% sildena®l, 2% placebo) and they were predominantly transient and mild or moderate in nature. These adverse events re¯ect the pharmacology of sildena®l as a phosphodiesterase type 5 inhibitor. No cases of priapism were reported. The rate of discontinuation due to adverse events (all causes) was comparable for patients treated with sildena®l (2.5%) and placebo (2.3%). In open-label extension studies, 90% of patients completed long-term sildena®l treatment, with only 2% withdrawing due to adverse events. Sildena®l is a well-tolerated oral treatment for erectile dysfunction.
Introduction
Sildena®l, an oral agent which has proven effective for the treatment of erectile dysfunction (ED), enables a natural erectile response to sexual stimulation by enhancing the relaxant effect of nitric oxide (NO) on the corpus cavernosum.
1,2 Normal penile erection involves the release of NO from nonadrenergic-noncholinergic nerves and endothelial cells of the cavernosal bodies. 3±5 NO activates guanylate cyclase, resulting in increased synthesis of cyclic guanosine monophosphate (cGMP), which induces corpus cavernosal smooth muscle relaxation, increased blood¯ow to the penis, increased intracavernosal pressure, and penile erection.
4±6
Sildena®l is a potent inhibitor of cGMP-speci®c phosphodiesterase (PDE) type 5, which is the predominant PDE isozyme responsible for the degradation of cGMP in the corpus cavernosum. 3, 7 When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE type 5 by sildena®l causes increased concentrations of cGMP in the corpus cavernosum. Sexual stimulation is required for sildena®l to produce its bene®cial pharmacological effects on erectile function.
For most patients, the recommended dosing regimen for sildena®l is 50 mg taken, as needed, approximately 1 h before sexual activity. However, sildena®l may be taken from 0.5 h±4 h before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day. Sildena®l is rapidly absorbed, with maximum observed plasma concentrations reached within 30±120 min (median 60 min) in the fasted state. The terminal phase half-life of sildena®l is 3±5 h. 7 Sildena®l has been shown to be ef®cacious in the treatment of ED of various aetiologies. 8 A series of 21 double-blind, placebo-controlled studies evaluated the overall safety and tolerability of sildena®l. Three of these studies differed markedly in design from the others, thereby preventing their inclusion in the pooling of the safety data. This article describes the data from the remaining 18 double-blind, placebocontrolled studies and 10 long-term, open-label studies in which sildena®l was administered to more than 3700 patients (with a total of 1631 years of exposure worldwide).
Methods
Safety and toleration data were analysed from 18 out of 21 randomised, double-blind, placebo-controlled (Phase II/III) studies of sildena®l (with 2355 patients receiving doses of 25 mg±100 mg) and 10 long-term, open-label studies of sildena®l in the treatment of ED of a variety of aetiologies (namely, organic, psychogenic, or mixed organic/psychogenic). In the 18 placebo-controlled studies, a total of 4274 patients (2722 sildena®l, 1552 placebo; age range 18±87 y) with ED (mean duration 5 y) received double-blind treatment of up to six months' duration. The 18 placebo-controlled studies had various designs (Table 1) , and included ®xed-dose and exible-dose regimens. The ®xed-dose studies assessed ef®cacy, safety, and tolerability by dose, and the¯exible-dose studies assessed these endpoints in dosing situations that most closely resemble those used in clinical practice. Patients were aged 18 y or older with broad-spectrum ED of more than six months' duration, including those with concomitant disease, such as diabetes, hypertension, and depression, and those who had previous prostate surgery. The main exclusion criteria were penile anatomical deformities, treatment with nitrates or anticoagulants, and any signi®cant concomitant medical condition that would impair the patient's ability to participate. Eighty-six percent (2340 out of 2722) of the patients treated with sildena®l took the drug on an as needed basis (PRN). However, patients were instructed not to take more than one dose daily. A total of 2199 patients received long-term, open-label sildena®l treatment for up to 1 y, including 1430 who had received double-blind sildena®l and 769 who had received double-blind placebo. Nitrate therapy was excluded in all of these studies since sildena®l potentiates the hypotensive effects of nitrates. The safety database for these 28 studies totalled 1631 y of sildena®l exposure.
In all studies evaluated for this analysis, investigators recorded the occurrence of observed and patient-reported adverse events throughout the course of treatment. The nature of the adverse events (mild, moderate, or severe) and their outcome were also recorded. Investigators were asked to classify the relationship of the adverse event to the study drug as de®nitely related, uncertain, or not related. In all studies, a treatment-related adverse event was de®ned as any event classi®ed as de®nitely related or of uncertain relation to the study drug. This classi®cation was also used when relationship data were missing. Serious adverse events included any event that suggested a signi®-cant hazard, such as those that were fatal, lifethreatening, permanently disabling, requiring hospitalisation, or that involved cancer, a congenital anomaly, or a drug overdose. Laboratory tests and blood pressure measurements were conducted at the screening visit, at regular intervals during study drug administration, and at the end of each study (®nal visit). In two of the placebo-controlled studies, electrocardiogram (ECG) recordings were obtained within 24 h of dosing.
Results

Adverse events
In PRN¯exible-dose, placebo-controlled studies, which re¯ect drug usage in clinical practice, the most commonly recorded adverse events of all causes reported by patients receiving sildena®l were headache (16%),¯ushing (10%), and dyspepsia (7%) ( Table 2 ). Nasal congestion, abnormal vision, diarrhoea, dizziness, and rash were also reported. The incidences of the most commonly recorded adverse events of all causes were higher in patients receiving sildena®l than in those receiving placebo. The overall rate of discontinuation from treatment due to adverse events of all causes in PRN exible-dose, placebo-controlled studies was comparable for patients in the sildena®l (2.5%) and placebo (2.3%) treatment groups. Headache (1.1%), ushing (0.4%), and nausea (0.4%) were the most common adverse events of all causes leading to discontinuation for patients receiving sildena®l. Only one patient in 2722 subjects treated with sildena®l discontinued treatment due to abnormal vision. Headache (0.4%) was the most common adverse event (all causes) leading to discontinuation for patients receiving placebo.
In PRN ®xed-dose, placebo-controlled studies, the majority of the adverse events were also mild or moderate and self-limiting in nature for both patients receiving sildena®l and those receiving placebo. In PRN ®xed-dose studies, the overall incidence of treatment-related adverse events and the incidences of the most commonly reported treatment-related adverse events (headache,¯ush-ing, dyspepsia, nasal congestion, abnormal vision, and dizziness) increased as the dose of sildena®l increased. The incidences of dyspepsia (17%) and abnormal vision (11%) were higher at 100 mg than at the lower doses of sildena®l in ®xed-dose studies. The most common description of abnormal vision was a mild and transient colour tinge to vision. The overall nature of adverse events was similar to that observed in the PRN¯exible-dose studies. The rates of discontinuation from treatment due to treatmentrelated adverse events were comparable at 25 mg (0.6%) and 50 mg (0.4%) of sildena®l and then increased at the 100 mg dose (1.2%); the corresponding rate for the placebo group was 1.0%. The most frequent adverse event causing discontinuation was headache in the ®xed-dose studies (0.6% in the 100 mg sildena®l group).
In the 10 long-term, open-label studies, 2199 patients received sildena®l. The majority of adverse events of all causes reported during these open-label studies were mild or moderate in nature, with the most common being headache (10%),¯ushing (9%), dyspepsia (6%), and respiratory tract infection (6%). The overall incidence of abnormal vision in openlabel extension studies was low (2%), with no longterm visual sequelae reported. The incidence and nature of the visual adverse events were similar in diabetic and nondiabetic patients. Only 10% of patients enrolled discontinued treatment prior to the end of the study for reasons that included loss to follow up, protocol violation, lack of ef®cacy, and adverse events. Adverse events of all causes accounted for 2% of the withdrawals over a 1 y period and lack of ef®cacy 4%. Headache was the most common adverse event (all causes) leading to discontinuation of treatment.
No cases of priapism were reported in any of the sildena®l studies.
Additional topics
PDE type 5 occurs in the systemic vasculature and as such the incidence of cardiovascular events following sildena®l therapy was of interest. In the 18 placebo-controlled studies, the incidence of cardiovascular adverse events other than¯ushing (described above) was 3.0% with sildena®l and 3.5% with placebo. Overall, 79% of all cardiovascular adverse events were mild, 16% were moderate, and only 6% were severe in nature for sildena®l, with a Clinical safety of oral sildena®l citrate (VIAGRA TM ) A Morales et al similar pattern for placebo. The rate of discontinuation of treatment due to cardiovascular adverse events was low and comparable for patients receiving sildena®l (0.9%) and those receiving placebo (0.9%) in the 18 placebo-controlled studies.
Of the 2722 patients receiving sildena®l in the 18 placebo-controlled studies, 885 (33%) were also taking antihypertensive medications. The tolerability of sildena®l treatment was comparable for patients taking antihypertensive medications and those not taking these medications.
The incidence rate (per 100 man-years of treatment) of serious cardiovascular adverse events was comparable for patients who received sildena®l in placebo-controlled studies (4.1; 95% CI 2.6±5.5), patients who received sildena®l in open-label extension studies (3.5; 95% CI 2.3±4.7), and patients who received placebo (5.7; 95% CI 3.3±8.2) ( Table  3 ). The rate of myocardial infarction was 1.7 per 100 man-years of treatment (95% CI 0.8±2.6) for patients treated with sildena®l in placebo-controlled studies compared with 1.4 per 100 man-years (95% CI 0.2± 2.6) for those receiving placebo, and 1.0 per 100 man-years (95% CI 0.3±1.6) for patients taking sildena®l in open-label extension studies. There were no serious adverse events of any type judged to be related to sildena®l treatment.
Pooled data from the 18 placebo-controlled studies indicated no change from baseline in the median value for systolic blood pressure, diastolic blood pressure, or heart rate for either the sildena®l group (n 2146) or the placebo group (n 1133).
There was no evidence of sildena®l-induced abnormalities in either ECG parameters or laboratory test measurements.
Discussion
Treatment with oral sildena®l was well tolerated, with no serious safety concerns identi®ed. Consistent with its known effects on the NO/cGMP pathway, sildena®l potentiates the hypotensive effects of nitrates. Patients taking organic nitrates were excluded from all 28 studies of sildena®l reported in this article. In man, basal NO plays an important role in the regulation of blood pressure via its arterial vasodilator effect. 9, 10 Sildena®l was well tolerated when administered alone or in combination with conventional antihypertensive agents. However, in Phase I studies in the presence of exogenously administered NO (namely, nitrates or NO donors), sildena®l administration was associated with clinically signi®cant decreases in blood pressure. Therefore, administration of sildena®l in patients who are concurrently using organic nitrates in any form is contraindicated.
The 28 studies reported included more than 3700 patients who received sildena®l and 1631 total years of sildena®l exposure worldwide. The PRN¯exible-dose studies provide safety information in a situation resembling dosing patterns in clinical practice, the PRN ®xed-dose studies provide insights on the safety of sildena®l by dose, and the open-label extension studies provide data on the long-term safety of sildena®l. Overall, the adverse events reported were transient, mild-to-moderate in nature, and rarely resulted in discontinuation of treatment. Safety data from the three double-blind, placebocontrolled studies not included in this analysis because of design differences were consistent with those reported here. No case of priapism was reported in any of the sildena®l studies.
The overall rate of discontinuation of treatment due to adverse events was low and comparable for patients receiving sildena®l at the recommended doses (25 mg±100 mg) and those receiving placebo in double-blind studies. In open-label extension studies, 90% of the patients enrolled completed longterm sildena®l therapy and only 2% withdrew due to adverse events of any cause. Sildena®l did not result in increased rates of myocardial infarction or other serious cardiovascular events during either short-term or long-term treatment. In fact, there were no serious adverse events related to sildena®l in the studies reported here. Furthermore, a study in which sildena®l was administered as needed for 16 weeks and then withdrawn demonstrated that there are no adverse effects associated with treatment withdrawal.
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The majority of the adverse events associated with sildena®l treatment are related to vasodilation (including headache,¯ushing, and nasal congestion), gastrointestinal events (dyspepsia), and visual effects (abnormal vision). All of these adverse events re¯ect the known pharmacological properties of sildena®l and, as would be expected, increase in incidence with increasing dose. Phase I studies showed that sildena®l has modest peripheral vasodilator properties, which can account for the occurrence of headache and¯ushing in some subjects. Nasal congestion is probably a result of Clinical safety of oral sildena®l citrate (VIAGRA TM ) A Morales et al hyperemia of the nasal mucosa, since PDE type 5 is located in the blood vessels of this tissue. The adverse events associated with vasodilation were generally mild or moderate in nature and rarely were a reason for discontinuation of treatment. In preclinical studies, sildena®l was shown to relax the isolated lower esophageal sphincter of dogs, indicating that PDE type 5 may have a role in maintaining the integrity of the gastro-esophageal junction. When characterised in clinical trials, the dyspepsia reported with sildena®l treatment was usually described as an occasional burning sensation in the epigastrium, suggesting that esophageal re¯ux may be the cause, as would be anticipated from the preclinical pharmacology. Although dose-related, the dyspepsia associated with sildena®l treatment was predominantly mild or moderate in nature. Preclinical studies also indicated that PDE type 6 of the retina plays an important role in the visual transduction pathway. Sildena®l demonstrates a 10-fold selectivity for human PDE type 5 over PDE type 6. 2 In studies in dogs, sildena®l produces a doserelated reversible effect on hyperpolarization of retinal tissue in response to light, consistent with the inhibition of retinal PDE type 6. Long-term safety studies with a speci®c emphasis on ocular safety conducted in rats, dogs, and mice have not revealed any functional or morphological changes in the retina and optical pathways. Clinical pharmacology studies demonstrated that the only acute effect of sildena®l was a mild, transient change in colour discrimination in the blue-green range in some subjects. Sildena®l had no effect on other objective measures of visual function, including visual acuity, contrast sensitivity, intraocular pressure, Amsler Grid, visual ®elds, and recovery from a photostress test. For patients in the placebo-controlled and open-label extension studies, abnormal vision (usually described as a transient colour tinge to vision) was generally mild-to-moderate in nature and resulted in only one case of treatment discontinuation at doses within the recommended range. In one study in which visual effects were studied intensively in a small number of patients over a 1 y period, no signi®cant change in any visual parameter was noted.
Conclusions
Sildena®l is a well-tolerated oral treatment for ED; its ef®cacy, excellent safety pro®le, lack of signi®-cant adverse events, convenient oral administration, and low rates of discontinuation from treatment suggest that sildena®l may be a valuable agent for the management of patients with ED.
Editorial comment
Clinical safety of oral sildena®l citrate (VIAGRA TM ) in the treatment of erectile dysfunctionÐby Morales et al This study clearly demonstrates that sildena®l is a safe drug and that it will probably gain wide acceptance in the population of male patients suffering from erectile dysfunction.
I think that in the near future every physician (from the family doctor to the specialist) must be ready to face a potentially overwhelming demand for this new drug. A critical issue will be to reinforce the concept that a careful search for the aetiology of erectile dysfunction is needed in the majority of patients in order to identify those who may bene®t from some forms of curative treatment (for example, sex therapy and vascular surgery) and to identify unknown medical conditions associated with erectile dysfunction.
A major effort should be made with the media in order to underline the concept that erectile dysfunction may be a signal of a serious disease and that the possiblity of offering a pill must not induce physicians to forget that the overall health conditions of the patient must primarily deserve the medical attention.
Francesco Montorsi MD
Clinical safety of oral sildena®l citrate (VIAGRA TM ) in the treatment of erectile dysfunctionÐby Morales et al
The editorial of®ce has given a high priority to a rapid, peer-reviewed, publication of this paper as the approval of this new compound by FDA in the US has occurred after only six months of consideration.
As we are observing the ®rst major GCP-study of a completely new concept it has been regarded important that the safety pro®le in short term studies in a large population with a wide scope in aetiology and age should be brought to the attention of the readers of this journal.
Two important questions are so far not addressed in this or earlier publications on oral sildena®l. The ®rst, which hopefully soon will be studied, is how effective is the drug going to be in a daily practice and how accepted will it be by patients in general as well as compared to other approved therapeutic medications.
The second question, which obviously will take several years to be answered: Will there be a different safety-pro®le after ®ve to ten years of use and will the compound still be effective after longterm use, as we know is the case with intracavernosal injections.
These questions will hopefully be studied as meticulously as the data presented in the present study, collected by a large number of investigators around the world.
It seems that most of the involved investigators have been thoroughly impressed by the immediate effectiveness of the compound in patients with a variety of aetiologies and this opens up two different questions: Who are the patients who do not repond to this treatment and secondly who are the patients who might have bene®ted from a permanent curative intervention (as mentioned in Dr. Montorsi's comment).
Globally only a few medically quali®ed persons have been properly trained in taking a thorough medical/sexological history.
Thus an enormous effort by the manufacturers of compounds active upon sexual functions as well as the medical educational institutions still has to be made in order to make the``professionals'' professional in something as elementary as their patients' sexual health.
Thus the new principle of treatment is highly interesting and certainly will bene®t a large group of patients as well as enriching the therapeutic armamentarium for the clinician.
G Wagner Editor
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